About Cavion
Cavion is a company based in Charlottesville (United States) founded in 2005 was acquired by Jazz Pharmaceuticals in August 2019. Cavion has raised $49.04 million across 8 funding rounds from investors including Jazz Pharmaceuticals, Lilly Ventures and Novartis Venture Fund. Cavion operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
- Headquarter Charlottesville, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$49.04 M (USD)
in 8 rounds
-
Latest Funding Round
$26.1 M (USD), Series A
Jan 12, 2017
-
Investors
Jazz Pharmaceuticals
& 4 more
-
Employee Count
Not available
-
Acquired by
Jazz Pharmaceuticals
(Aug 12, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Cavion
Unlock access to complete
Unlock access to complete
Funding Insights of Cavion
Cavion has successfully raised a total of $49.04M across 8 strategic funding rounds. The most recent funding activity was a Series A round of $26.1 million completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cavion
Cavion has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Jazz Pharmaceuticals, Lilly Ventures and Novartis Venture Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage life sciences investments are targeted in the healthcare sector.
|
Locked | Locked | Locked | |
|
Investments are made in innovative life science companies globally.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Cavion
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cavion
Investment portfolio details for Cavion
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cavion
Detailed financials for Cavion
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cavion Comparisons
Peer comparison for Cavion
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cavion
Cavion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Drugs for CNS disorders are developed and advanced.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
Detailed competitors of Cavion
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cavion
Complete news archive for Cavion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cavion
Cavion was founded in 2005 and raised its 1st funding round 2 years after it was founded.
Cavion is headquartered in Charlottesville, United States. It is registered at Charlottesville, Virginia, United States.
Cavion is a funded company, having raised a total of $49.04M across 8 funding rounds to date.
Cavion was founded in 2005 and is based in Charlottesville, United States. Small molecule drugs for neurological disorders are developed by targeting the Cav3 molecule in T-type calcium channels. Lead candidates are advanced to phase 3 clinical trials for neuropathic pain management. Another candidate, mibefradil, is evaluated in phase II trials for recurrent glioblastoma multiforme, a form of brain cancer.
Cavion's top competitors include Jazz Pharmaceuticals, Neurocrine and Biohaven Pharmaceutical.
Cavion has 5 investors. Key investors include Jazz Pharmaceuticals, Lilly Ventures, Novartis Venture Fund, Enso Ventures, and Center for Innovative Technology.